Lundbeck is committed to patient access and providing support through a VYEPTI CONNECT liaison or a field reimbursement specialist. Below are resources that may be helpful.

Downloadable resources

files selected

Clear

VYEPTI CONNECT Enrollment Form

Download the enrollment form and begin the benefits investigation process.

VYEPTI CONNECT Overview

Download information about VYEPTI CONNECT. This optional program offers access support throughout the treatment journey.

Physician Attestation

Physicians with patients who do not wish to enroll in VYEPTI CONNECT but still want access support from a Field Reimbursement Specialist should download and submit this form.

California Patient Attestation

Providers in California who have prescribed VYEPTI must have their patients fill out this form and submit it along with the VYEPTI CONNECT Enrollment Form.

How to Order VYEPTI Under the Medical Benefit

Information about the ordering and distribution of VYEPTI under the medical benefit.

Billing and Coding Guide

Information that may be helpful when submitting claims for VYEPTI.

Prior Authorization (PA) Checklist

Information that may help you organize material that may be needed to complete a PA for VYEPTI.

Sample Letter of Medical Necessity

Information about what may be needed to complete a Letter of Medical Necessity.

Sample Letter of Appeal

Information about what may be needed to complete a Letter of Appeal.

Sample Letter of Medical Exception

Information about what may be needed to complete a Letter of Medical Exception.

Site of Care Transition Form

Download and share with patients about their next site of care.

Specialty Pharmacy Checklist

Information on how to successfully submit all necessary information to a specialty pharmacy for a patient's prescription.

VYEPTI Copay Assistance Program Overview

Information on eligibility requirements and how your commercial patients can enroll in the program.

VYEPTI CONNECT Terms and Conditions

Review the Terms and Conditions for VYEPTI CONNECT support.

VYEPTI Copay Assistance Program Terms and Conditions

Review the Terms and Conditions for VYEPTI Copay Assistance Program.

The resources on this page are for informational purposes only and are not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

Want to hear when more resources become available?

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.